袖状胃切除术是一种在生理上错误的手术，是"对真主造物的僭越"，因为胃不是一个袋子，而是一个内分泌、肌肉和免疫器官，它的功能会丧失。
原始表述
قلت يا جماعه التكميم عمليه فيها تعدي على خلق الاله اصلا انت بتقص معده فاكرها كيس بتصغر غاره لا هي مش كيس ده نسيج غدد صماء بتفرز هرمونات حضرتك جاسترين وبتفرز هرمون هيستامين
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
袖状胃切除术是一种在生理上错误的手术，是"对真主造物的僭越"，因为胃不是一个袋子，而是一个内分泌、肌肉和免疫器官，它的功能会丧失。
出处
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- المرض المستحدث (打开来源)
- 发布日期
- 2025年12月22日
- 时间戳
- 0:07:13 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); wording may contain transcription errors; no timestamps available.
- 所声称的机制
Loss of gastric endocrine, digestive and immune (acid barrier) function.
- 所声称的健康影响
Multiple diseases.
- 涉及人群
All sleeve patients
- Elawady 设定的地域限制
none found
来源版本存在差异
- 来源状态
- 档案网站引语（未注明出处）
- 归属
- Elawady (archive paraphrase; source video not given)
- 出处
- https://eltayebat.com/rule/bariatric-surgery/
- 归属的不确定性
- The archive attributes this wording to Dr. Diaa but gives no video reference.
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr.D Clinics - Diaa Al Awady is live!التكميم (打开来源)
- 发布日期
- 2025年5月6日
- 时间戳
- 无（转录文本不含时间信息）
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); wording may contain transcription errors; no timestamps available.
科学评估
基本错误 – 该说法的主要部分没有证据支持，或被严重夸大。
证据确定性: 低 – 进一步研究很可能大幅改变该评估。
1. 说法是什么？
That sleeve destroys the stomach's functions and is therefore wrong in principle.
2. 哪些内容可证实是正确的？
The stomach does have endocrine functions (e.g., gastrin, histamine-producing cells) and an acid barrier; sleeve gastrectomy permanently alters anatomy and physiology, with documented consequences (reflux, gallstones, and nutrient deficiencies, which are however more frequent after bypass or BPD than after sleeve, A-BAR-20).
3. 哪些内容是错误或夸大的？
The stomach does not lose its functions: acid production continues (reflux is the main problem), and digestion and absorption continue with supplementation. Outcome data show average net benefit in severe obesity (lower mortality, I-BAR-01; diabetes improvement, A-BAR-24). The statement that 'nobody should cut a working part of the body' is a value judgement, not a scientific finding.
4. 哪些内容仍不明确？
The theological and moral framing ('transgression against creation') is outside the scope of a scientific fact-check.
5. 哪些研究支持该说法？
A-BAR-07 (reflux). Physiology premise: gut hormones change after sleeve (ghrelin down, GLP-1/PYY up; I-BAR-147) and gastric emptying accelerates (I-BAR-148); iron deficiency rises over years (I-BAR-120). These show altered, not lost, function.
6. 哪些研究与该说法相矛盾？
I-BAR-01, A-BAR-05, A-BAR-24; sleeve-specific lower mortality vs usual care (I-BAR-101, I-BAR-102); A-BAR-20 (pylorus preserved; less anaemia after sleeve than bypass/BPD).
7. 对德国和欧洲而言情况如何？
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
8. 关于埃及的已知情况是什么？
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
9. 合理的实际结论是什么？
袖状胃切除术有真实的生理学缺点，患者应当了解；它并非没有功能损失，但没有证据表明它对有适应证的患者总体上是有害的。
评估详情
- 证据确定性的依据
The physiological premise is partly correct but the conclusion ('functions lost', net harm) conflicts with outcome data; the religious/moral component cannot be assessed scientifically.
- 来源质量
Elawady's reasoning from physiology without outcome data. The archive quote ('physiological transgression', 'lethal', 'crime', 'wrong idea', stomach 'pouch' turned into a 'tube') is consistent with transcripts (0ScIsnGw5cU, khw1PTnCL-M, E3fDJyXYP7E).
- 地区可推广性
Universal.
- 个体例外情况
Some individuals develop severe reflux, deficiencies or other complications that make the operation harmful for them.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
缺乏高质量证据支持 – 没有良好证据支持该说法；但仅凭这一点并不能证明它是错误的。
研究问题: Does sleeve gastrectomy destroy the endocrine, muscular and immune functions of the stomach such that the operation causes net harm (is physiologically wrong) in people with severe obesity?
研究问题详解 (PICO)
- 人群
- Adults with severe obesity
- 干预或暴露
- Sleeve gastrectomy
- 对照
- Preoperative physiology; non-operated people with obesity
- 地域范围
- universal biology; the religious/moral component is outside scientific assessment
- 结局指标
- Gastric hormone secretion and motility
- Nutrient status
- All-cause mortality and major outcomes
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Meta-analysis: gut hormones after sleeve
Meta-analysis: hormone output changes after sleeve (ghrelin down, GLP-1/PYY up) - confirms the stomach is an endocrine organ altered by surgery.
- 实际结果
- Ghrelin Hedges' g -1.49; GLP-1 +1.10; PYY +1.40.
- 方法学质量
- moderate
- 相关性
- supports the premise only
- 局限
- Changes are linked to benefit, not harm
Finnish trial: sleeve vs bypass after 10 years
SLEEVEPASS: oesophagitis 31% vs 7% after bypass - a real functional downside.
- 实际结果
- 31% vs 7%.
- 方法学质量
- high
- 相关性
- indirect (one harm)
- 局限
- Comparison with bypass
Meta-analysis: anaemia after sleeve
Iron deficiency and anaemia rise after sleeve.
- 实际结果
- Anaemia 18-25% at 3-5 y.
- 方法学质量
- moderate
- 相关性
- indirect (functional consequence)
- 局限
- Observational
哪些证据不支持该说法？
Israeli study: deaths after sleeve, bypass and banding vs usual care
Sleeve patients had lower mortality than matched usual-care patients.
- 实际结果
- Surgery vs control HR ~0.62 (0.40-0.98) for sleeve.
- 方法学质量
- moderate
- 相关性
- direct for net harm
- 局限
- Short follow-up
US study: survival after sleeve and bypass
Sleeve associated with lower 5-y mortality vs matched controls.
- 实际结果
- HR 0.28 (0.13-0.57).
- 方法学质量
- moderate
- 相关性
- direct
- 局限
- Attrition
Meta-analysis: weight-loss surgery and survival
Meta-analysis: longer life after surgery, similar across sleeve, bypass and banding.
- 实际结果
- +6.1 years.
- 方法学质量
- moderate-high
- 相关性
- direct
- 局限
- Observational
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
The stomach is indeed a hormonal and muscular organ and sleeve gastrectomy permanently changes it, with real downsides (reflux, iron deficiency); but its functions are altered rather than lost, and on average outcomes in severe obesity are better, not worse.
为什么有些研究权重更大
Outcome studies (mortality, morbidity) answer the "net harm" question; physiological studies only support the premise.
因果关系是否已确立？ 尚未确立 No evidence that loss of gastric function causes net harm; hormonal changes are part of the therapeutic mechanism.
仍存在的不确定性
Very long-term consequences of altered gastric physiology (e.g., Barrett, iron status).
合理的结论
Premise partly correct; conclusion not supported; theological component not assessable.
为什么研究结果看起来互相矛盾？
Physiological change (premise) and net clinical benefit (outcomes) are not contradictory: the same hormonal changes contribute to weight loss and diabetes improvement.
这是否取决于国家？
- 一般生物学效应
- Universal.
- 饮食习惯
- Not applicable (surgical procedure, not a food).
- 食品原产地
- Not applicable (surgical procedure, not a food).
- 污染物
- Not applicable (surgical procedure, not a food).
- 本国生产条件
- Not applicable.
- 法律规则
- Not applicable.
- 实际监测数据
- Not applicable.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Sleeve-specific HR inversion – Surgery vs control 0.62 (0.40-0.98). 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Net clinical harm of sleeve gastrectomy (mortality) vs usual care
- 起始等级
- 低（观察性研究）
- 降级理由
- indirectness to the physiological claim
- 升级理由
- large effect
- 结果
- 低
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ASMBS/IFSO: 2022 ASMBS and IFSO Indications for Metabolic and Bariatric Surgery (I-BAR-11) (2022) · 原始文献
Metabolic and bariatric surgery is recommended for BMI >35 regardless of comorbidities and should be considered for BMI 30-34.9 with metabolic disease; long-term results consistently demonstrate safety and efficacy (abstract; erratum noted in PubMed). - NICE: Overweight and obesity management (NG246), section 1.18 Bariatric surgery (2025 (last updated 8 Jan 2026)) · 原始文献
Offer referral for bariatric surgery assessment with BMI >=40, or 35-39.9 with a significant weight-related condition, if the person agrees to lifelong follow-up; lower thresholds by 2.5 for people of Middle Eastern, South Asian, Chinese and Black African/Caribbean background; follow-up >=2 years in the bariatric service and at least annual nutritional monitoring and supplementation afterwards.
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| PubMed | 2026年10月26日 | (sleeve gastrectomy[ti]) AND (ghrelin[tiab] OR gastric acid secretion[tiab] OR parietal[tiab] OR gastrin[tiab]) AND (human* OR patients) | 支持性证据 | 137 | |
| Europe PMC | 2026年10月26日 | TITLE:"sleeve gastrectomy" AND (TITLE:"ghrelin" OR TITLE:"gastrin" OR TITLE:"acid secretion" OR TITLE:"gastric emptying" OR TITLE:"hormone*") AND (PUB_TYPE:"Meta-Analysis" OR PUB_TYPE:"Review" OR TITLE:"systematic review") | 双向 | 4 | |
| Europe PMC | 2026年10月26日 | (TITLE:"sleeve gastrectomy") AND (TITLE:"mortality" OR TITLE:"survival") AND (TITLE:"usual care" OR TITLE:"nonsurgical" OR TITLE:"matched" OR TITLE:"cohort") | 反对性证据 | 4 | |
| PubMed | 2026年10月26日 | (sleeve gastrectomy[ti] OR bariatric[ti]) AND (all-cause mortality[ti] OR long-term mortality[ti]) AND (usual care OR nonsurgical OR matched controls) | 反对性证据 | 9 |
待解决的问题
Long-term gastric physiology after sleeve (acid secretion, iron absorption).
核查深度如何？
11 项相关研究：5 项核查了全文（其中 2 项进行了结构化偏倚风险评估），6 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 基本错误 (低)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 基本错误 (低)
Unchanged (MOSTLY_FALSE, low). Sleeve-specific mortality data strengthen the contradiction of "net harm"; hormone meta-analysis confirms the premise. Certainty kept low because the claim bundles physiology, value judgement and religious framing.
新来源: I-BAR-101 I-BAR-102 I-BAR-120 I-BAR-147 I-BAR-148
通俗解释
Elawady 认为，胃不是一个简单的袋子，而是一个能产生激素的肌性和免疫器官，切掉它是错误的。确实，胃的作用远不止储存食物，袖状胃切除术会永久改变它，并有反流和维生素缺乏等已知的副作用。但手术后胃仍在工作，大型研究显示，平均而言，重度肥胖者术后活得更久。宗教方面的论点无法用科学来检验。
与该说法相关的研究
支持该说法的研究 (1)
-
Finnish trial: sleeve vs bypass after 10 years
Salminen P et al.. JAMA Surg 2022 · PMID 35731535 · DOI 10.1001/jamasurg.2022.2229随机对照试验被 Tayebat 档案网站引用已核查摘要★ 关键研究Esophagitis was found in 31% after sleeve vs 7% after bypass; Barrett's esophagus was 4% in both groups.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare sleeve vs bypass
- 研究是如何开展的？
RCT with 10-year follow-up
- 研究了多少人、动物或样本？
240 patients
- 实际发现了什么？
More esophagitis after sleeve; Barrett's equal
- 观察到的效应有多大？
31% vs 7%; BE 4% vs 4%
- 研究结果对日常生活意味着什么？
Sleeve often causes reflux damage; bypass less so
- 该研究有哪些局限？
Attrition; small
- 它对 Elawady 的具体说法说明了什么？
Supports reflux claim, not sleeve-specific Barrett's
- 研究结果是否适用于德国和欧洲？
Directly European
- 从该研究中明确不能得出什么结论？
Cancer risk
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (7)
-
Meta-analysis: weight-loss surgery and survival
Syn NL et al.. Lancet 2021 · PMID 33965067 · DOI 10.1016/S0140-6736(21)00591-2Meta分析独立交叉核查已核查摘要★ 关键研究Across 174,772 people, surgery was linked to about half the risk of death and about 6 more years of median life expectancy; sleeve showed similar effects to bypass.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Survival
- 研究是如何开展的？
Meta-analysis of matched cohorts
- 研究了多少人、动物或样本？
174,772
- 实际发现了什么？
Lower mortality
- 观察到的效应有多大？
HR ~0.51; +6.1 years
- 研究结果对日常生活意味着什么？
Surgery is linked to longer, not shorter, life in severe obesity
- 该研究有哪些局限？
Observational studies
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'lethal'
- 研究结果是否适用于德国和欧洲？
Includes Europe
- 从该研究中明确不能得出什么结论？
Exact causal size
-
Swedish 24-year study: surgery added about 3 years of life
Carlsson LMS et al.. N Engl J Med 2020 · PMID 33053284 · DOI 10.1056/NEJMoa2002449队列研究被 Tayebat 档案网站引用已核查全文★ 关键研究Operated patients lived about 3 years longer than non-operated patients with obesity, but still about 5.5 years less than the general population (non-operated: about 8.5 years less).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Life expectancy
- 研究是如何开展的？
Prospective controlled cohort with population reference
- 研究了多少人、动物或样本？
5182 people
- 实际发现了什么？
Surgery gained 3 years; gap to population 5.5 vs 8.5 years
- 观察到的效应有多大？
HR death 0.77; +3.0 years
- 研究结果对日常生活意味着什么？
Surgery reduced but did not remove the life-expectancy loss linked to severe obesity
- 该研究有哪些局限？
Not randomized; old operations
- 它对 Elawady 的具体说法说明了什么？
Number correct, implication 'surgery shortens life' wrong
- 研究结果是否适用于德国和欧洲？
Directly European
- 从该研究中明确不能得出什么结论？
That surgery causes the remaining 5.5-year gap
-
STAMPEDE: surgery vs medicines for diabetes
Schauer PR et al.. N Engl J Med 2017 · PMID 28199805 · DOI 10.1056/NEJMoa1600869随机对照试验被 Tayebat 档案网站引用全文，含结构化偏倚风险评估After 5 years, 23-29% of operated patients reached near-normal HbA1c vs 5% with medicines alone.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Diabetes RCT
- 研究是如何开展的？
RCT
- 研究了多少人、动物或样本？
150
- 实际发现了什么？
Surgery better
- 观察到的效应有多大？
29%/23% vs 5%
- 研究结果对日常生活意味着什么？
Surgery helps more, but most did not reach the target and only 15-22% reached it without diabetes medicines
- 该研究有哪些局限？
Small single-centre trial; not blinded; more drop-outs in the medical group; ITT result not significant
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'benefit erodes away'
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Hard outcomes
-
When is weight-loss surgery recommended?
Eisenberg D et al.. Obes Surg 2023 · PMID 36336720 · DOI 10.1007/s11695-022-06332-1指南 / 立场声明独立交叉核查已核查摘要Surgical societies recommend it for BMI above 35 and consider it from BMI 30 with metabolic disease.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Indications
- 研究是如何开展的？
Society statement
- 研究了多少人、动物或样本？
n/a
- 实际发现了什么？
BMI thresholds
- 观察到的效应有多大？
n/a
- 研究结果对日常生活意味着什么？
Surgery is for defined indications
- 该研究有哪些局限？
Professional society
- 它对 Elawady 的具体说法说明了什么？
Contradicts blanket rejection
- 研究结果是否适用于德国和欧洲？
International
- 从该研究中明确不能得出什么结论？
Individual decisions
-
Review: nutrition after weight-loss surgery
Lupoli R et al.. World J Diabetes 2017 · PMID 29204255 · DOI 10.4239/wjd.v8.i11.464叙述性综述被 Tayebat 档案网站引用全文，含结构化偏倚风险评估Deficiencies are common but can be prevented with lifelong supplements and monitoring.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Review
- 研究是如何开展的？
Narrative
- 研究了多少人、动物或样本？
n/a
- 实际发现了什么？
Deficiencies (iron, B12, vitamin D, calcium, protein) are common, especially after bypass/BPD; many exist before surgery
- 观察到的效应有多大？
n/a
- 研究结果对日常生活意味着什么？
Supplements are required
- 该研究有哪些局限？
Narrative
- 它对 Elawady 的具体说法说明了什么？
Supports with context
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Exact rates; that all procedures cause the same deficiencies; that sleeve abolishes stomach function
-
Israeli study: deaths after sleeve, bypass and banding vs usual care
Reges et al.. JAMA 2018 · PMID 29340677 · DOI 10.1001/jama.2017.20513队列研究独立交叉核查已核查全文★ 关键研究People who had surgery, including sleeve, died less often over about 4 years than similar people with obesity who did not (sleeve 0.8% vs 1.3%).
Outcome data contradict net harm of sleeve.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare death rates after three operations with usual care
- 研究是如何开展的？
Matched cohort from health-fund records
- 研究了多少人、动物或样本？
8,385 operated, 25,155 controls
- 实际发现了什么？
Lower mortality with every operation, including sleeve
- 观察到的效应有多大？
Sleeve: HR about 0.62 (surgery vs control)
- 研究结果对日常生活意味着什么？
On average, sleeve did not shorten life in the first years
- 该研究有哪些局限？
Observational; short follow-up for sleeve
- 它对 Elawady 的具体说法说明了什么？
Contradicts "sleeve is lethal"
- 研究结果是否适用于德国和欧洲？
Health-system data from Israel; plausible for Europe
- 从该研究中明确不能得出什么结论？
Cannot prove causation or show very long-term effects
-
US study: survival after sleeve and bypass
Courcoulas et al.. Ann Surg 2023 · PMID 34387200 · DOI 10.1097/SLA.0000000000005155队列研究独立交叉核查已核查全文★ 关键研究Over 5 years, people who had a sleeve died about 70% less often than similar people who did not have surgery (1.0% vs 2.7%).
Outcome data contradict net harm of sleeve.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare deaths after SG/RYGB with matched non-operated patients
- 研究是如何开展的？
Matched cohort, health records
- 研究了多少人、动物或样本？
13,900 SG; 17,258 RYGB; 87,965 controls
- 实际发现了什么？
Lower death rates after both operations
- 观察到的效应有多大？
SG HR 0.28 (0.13-0.57)
- 研究结果对日常生活意味着什么？
Sleeve was not associated with earlier death
- 该研究有哪些局限？
About one third lost to follow-up; observational
- 它对 Elawady 的具体说法说明了什么？
Contradicts "sleeve kills"
- 研究结果是否适用于德国和欧洲？
Plausible for Europe and Egypt
- 从该研究中明确不能得出什么结论？
Cannot exclude unmeasured confounding
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (3)
-
Meta-analysis: anaemia after sleeve
Nie et al.. Obes Rev 2023 · PMID 36323610 · DOI 10.1111/obr.13516Meta分析独立交叉核查已核查摘要★ 关键研究About 1 in 5 sleeve patients had anaemia 4-5 years after surgery, mostly from iron deficiency; B12 and folate deficiency stayed rare.
Sleeve alters iron handling - a real functional consequence.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Track deficiencies after SG
- 研究是如何开展的？
Meta-analysis
- 研究了多少人、动物或样本？
7,639
- 实际发现了什么？
Anaemia rising to 18-25%
- 观察到的效应有多大？
Proportions
- 研究结果对日常生活意味着什么？
Iron checks and supplements matter after sleeve
- 该研究有哪些局限？
Observational
- 它对 Elawady 的具体说法说明了什么？
Supports iron part; limits B12 part for sleeve
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Whether everyone is affected
-
Meta-analysis: gut hormones after sleeve
McCarty et al.. Ann Surg 2020 · PMID 31592891 · DOI 10.1097/SLA.0000000000003614Meta分析独立交叉核查已核查摘要After sleeve the hunger hormone ghrelin fell and satiety hormones GLP-1 and PYY rose.
Ghrelin falls and GLP-1/PYY rise after sleeve: endocrine function changes (premise correct), changes are mechanistically beneficial.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Hormone changes after SG
- 研究是如何开展的？
Meta-analysis
- 研究了多少人、动物或样本？
653
- 实际发现了什么？
Ghrelin down, GLP-1/PYY up
- 观察到的效应有多大？
Hedges' g -1.49 (ghrelin)
- 研究结果对日常生活意味着什么？
The stomach is a hormone organ; surgery changes it
- 该研究有哪些局限？
Short follow-up
- 它对 Elawady 的具体说法说明了什么？
Premise correct, conclusion not
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Long-term health effects
-
Review: how the gut works after sleeve or bypass
Steenackers et al.. Lancet Gastroenterol Hepatol 2021 · PMID 33581761 · DOI 10.1016/S2468-1253(20)30302-2叙述性综述独立交叉核查已核查摘要After sleeve, food leaves the stomach faster and bile acids rise; many other effects are still unknown.
SG changes gastric emptying and transit; many effects unknown.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
GI physiology after surgery
- 研究是如何开展的？
Narrative review
- 研究了多少人、动物或样本？
not applicable
- 实际发现了什么？
Faster emptying; unknowns
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
The stomach changes but keeps working
- 该研究有哪些局限？
Not systematic
- 它对 Elawady 的具体说法说明了什么？
Premise partly correct
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Harm or benefit
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
埃及
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
在我的国家适用什么？
一般科学评估
基本错误 生理学前提部分正确；但"袖状胃切除术在原则上是错误的"这一结论没有得到结局数据的支持。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial.. Salminen P et al.. JAMA Surg 2022 · PMID 35731535 · DOI 10.1001/jamasurg.2022.2229
- Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants.. Syn NL et al.. Lancet 2021 · PMID 33965067 · DOI 10.1016/S0140-6736(21)00591-2
- Life Expectancy after Bariatric Surgery in the Swedish Obese Subjects Study.. Carlsson LMS et al.. N Engl J Med 2020 · PMID 33053284 · DOI 10.1056/NEJMoa2002449
- Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes.. Schauer PR et al.. N Engl J Med 2017 · PMID 28199805 · DOI 10.1056/NEJMoa1600869
- 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery.. Eisenberg D et al.. Obes Surg 2023 · PMID 36336720 · DOI 10.1007/s11695-022-06332-1
- Bariatric surgery and long-term nutritional issues.. Lupoli R et al.. World J Diabetes 2017 · PMID 29204255 · DOI 10.4239/wjd.v8.i11.464
- Association of Bariatric Surgery Using Laparoscopic Banding, Roux-en-Y Gastric Bypass, or Laparoscopic Sleeve Gastrectomy vs Usual Care Obesity Management With All-Cause Mortality.. Reges et al.. JAMA 2018 · PMID 29340677 · DOI 10.1001/jama.2017.20513
- Reduction in Long-term Mortality After Sleeve Gastrectomy and Gastric Bypass Compared to Nonsurgical Patients With Severe Obesity.. Courcoulas et al.. Ann Surg 2023 · PMID 34387200 · DOI 10.1097/SLA.0000000000005155
- Prevalence of anemia and related nutrient deficiencies after sleeve gastrectomy: A systematic review and meta-analysis.. Nie et al.. Obes Rev 2023 · PMID 36323610 · DOI 10.1111/obr.13516
- Effect of Sleeve Gastrectomy on Ghrelin, GLP-1, PYY, and GIP Gut Hormones: A Systematic Review and Meta-analysis.. McCarty et al.. Ann Surg 2020 · PMID 31592891 · DOI 10.1097/SLA.0000000000003614
- Adaptations in gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass.. Steenackers et al.. Lancet Gastroenterol Hepatol 2021 · PMID 33581761 · DOI 10.1016/S2468-1253(20)30302-2